ORM-12741
ORM-12741 is a pharmaceutical drug with 10 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 10 completed trials
Phase Distribution
Phase Distribution
8
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
10 of 10 finished
0.0%
0 ended early
0
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease
Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers
Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease
Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741
Safety and Tolerability Study With Single Ascending Doses of ORM-12741
Clinical Trials (10)
Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease
Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers
Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease
Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741
Safety and Tolerability Study With Single Ascending Doses of ORM-12741
A PET Study With ORM-12741
Pharmacokinetic Study of ORM-12741 in Healthy Volunteers
Early Phase I Microdosing Study of ORM-14540 and ORM-12741
Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741
Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10